Skip to Main Content

Author Details

John M Maris
Children's Hospital of Philadelphia
1985
437
95
PMIDPaper TitleJournal TitlePublished Year
37812652Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma.Clin Cancer Res2024
37812652Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma.Clin Cancer Res2024
37885116Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to <sup>131</sup> I-MIBG in patients with relapsed/refractory neuroblastoma.Pediatr Blood Cancer2024
37688579Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.J Natl Cancer Inst2024
37688570BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.J Natl Cancer Inst2024
37885116Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to <sup>131</sup> I-MIBG in patients with relapsed/refractory neuroblastoma.Pediatr Blood Cancer2024
37688579Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.J Natl Cancer Inst2024
37688570BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.J Natl Cancer Inst2024
36335266Dr Audrey E. Evans (1925-2022): academic trailblazer par excellence.Pediatr Res2023
36335266Dr Audrey E. Evans (1925-2022): academic trailblazer par excellence.Pediatr Res2023
38039376Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion.Sci Immunol2023
37938771Targeting of intracellular oncoproteins with peptide-centric CARs.Nature2023
37584517Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors.Cancer Res2023
37774704Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.Cell Rep Med2023
37611092A MYCN-independent mechanism mediating secretome reprogramming and metastasis in <i>MYCN</i>-amplified neuroblastoma.Sci Adv2023
36909587Genetic Predisposition to Neuroblastoma Results from a Regulatory Polymorphism that Promotes the Adrenergic Cell State.bioRxiv2023
36778420<i>BARD1</i> germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.bioRxiv2023
37147298Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.Nat Commun2023
37081608Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.Cancer2023
36822669KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.J Immunother Cancer2023
37012551Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.Nat Med2023
36747619Germline pathogenic variants in 786 neuroblastoma patients.medRxiv2023
37183825Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell state.J Clin Invest2023
37516886ROGUE: an R Shiny app for RNA sequencing analysis and biomarker discovery.BMC Bioinformatics2023
37292750Structural principles of peptide-centric Chimeric Antigen Receptor recognition guide therapeutic expansion.bioRxiv2023
37098238Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.J Clin Oncol2023
36524612In memoriam: Dr. Audrey E. Evans.Pediatr Blood Cancer2023
37516886ROGUE: an R Shiny app for RNA sequencing analysis and biomarker discovery.BMC Bioinformatics2023
37584517Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors.Cancer Res2023
37611092A MYCN-independent mechanism mediating secretome reprogramming and metastasis in <i>MYCN</i>-amplified neuroblastoma.Sci Adv2023
37938771Targeting of intracellular oncoproteins with peptide-centric CARs.Nature2023
37774704Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.Cell Rep Med2023
38039376Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion.Sci Immunol2023
37292750Structural principles of peptide-centric Chimeric Antigen Receptor recognition guide therapeutic expansion.bioRxiv2023
37183825Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell state.J Clin Invest2023
37081608Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.Cancer2023
37147298Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.Nat Commun2023
37012551Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.Nat Med2023
37098238Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.J Clin Oncol2023
36747619Germline pathogenic variants in 786 neuroblastoma patients.medRxiv2023
36778420<i>BARD1</i> germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.bioRxiv2023
36909587Genetic Predisposition to Neuroblastoma Results from a Regulatory Polymorphism that Promotes the Adrenergic Cell State.bioRxiv2023
36822669KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.J Immunother Cancer2023
36524612In memoriam: Dr. Audrey E. Evans.Pediatr Blood Cancer2023
34788385DNMT3A overgrowth syndrome is associated with the development of hematopoietic malignancies in children and young adults.Blood2022
36108156Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.Cancer Discov2022
36175618Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma.Br J Cancer2022
35839426Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.J Clin Oncol2022
36167467Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.J Immunother Cancer2022
35484988Paraneoplastic myasthenia gravis and pemphigus associated with follicular dendritic cell sarcoma leading to cardiorespiratory collapse in a 7-year-old.Pediatr Blood Cancer2022
  • 1 - 50 of 874

Recommended Authors

The Chinese University of Hong Kong, Prince of Wales Hospital
Career Start Year 2010
Number of shared co-authors 41
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 2010
Number of shared co-authors 54
Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg University
Career Start Year 2009
Number of shared co-authors 49
Curie Institute Hospital Group
Career Start Year 2008
Number of shared co-authors 33
Dana-Farber Cancer Institute
Career Start Year 2008
Number of shared co-authors 45
Emory School of Medicine
Career Start Year 2008
Number of shared co-authors 9
Arnold Palmer Hospital for Children
Career Start Year 2003
Number of shared co-authors 41
Perth Children's Hospital
Career Start Year 2002
Number of shared co-authors 34
Institut Curie Hospital
Career Start Year 2001
Number of shared co-authors 20
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 2001
Number of shared co-authors 98
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 42
Dana-Farber Cancer Institute
Career Start Year 1999
Number of shared co-authors 59
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 1998
Number of shared co-authors 55
Vanderbilt University Medical Center
Career Start Year 1998
Number of shared co-authors 10
Brain Tumor Institute, Children's National Hospital
Career Start Year 1998
Number of shared co-authors 49
Hasbro Children's Hospital, Brown University.
Career Start Year 1997
Number of shared co-authors 41
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 16
Texas Children's Hospital
Career Start Year 1996
Number of shared co-authors 50
Center for Biomedical Informatics and Information Technology
Career Start Year 1996
Number of shared co-authors 31
USA University of Zurich
Career Start Year 1995
Number of shared co-authors 42
University Children's Hospital
Career Start Year 1994
Number of shared co-authors 42
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 1993
Number of shared co-authors 59
McGill University Health Centre (MUHC), Montreal Children's Hospital (MCH)
Career Start Year 1991
Number of shared co-authors 70
Hopp Children's Cancer Center (KiTZ)
Career Start Year 1990
Number of shared co-authors 83
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 26
Ruth Rappaport Children's Hospital
Career Start Year 1988
Number of shared co-authors 9
Toronto General Hospital, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 4
Children's Hospital at Montefiore.
Career Start Year 1986
Number of shared co-authors 9
Clinical Research Division, Fred Hutchinson Cancer Center
Career Start Year 1985
Number of shared co-authors 53
Children's Cancer Therapy Development Institute
Career Start Year 1980
Number of shared co-authors 14

Collaborators

National Cancer Institute
Co-authored papers 83
Cancer Center, Texas Tech University Health Sciences Center
Co-authored papers 83
The University of Texas Health Science Center at San Antonio
Co-authored papers 71
Co-authored papers 67
University of Texas MD Anderson Cancer Center
Co-authored papers 67
Co-authored papers 61
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Co-authored papers 58
Children's Hospital of Philadelphia
Co-authored papers 52
Perelman School of Medicine at the University of Pennsylvania
Co-authored papers 50
Co-authored papers 47
Co-authored papers 45
St. Jude Children's Research Hospital.
Co-authored papers 42
The University of Texas Health Science Center at San Antonio
Co-authored papers 31
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 29
Dana-Farber Cancer Institute
Co-authored papers 26
Co-authored papers 24
The Center for Applied Genomics, Children's Hospital of Philadelphia
Co-authored papers 23
Perelman School of Medicine at the University of Pennsylvania
Co-authored papers 21
California Polytechnic State University
Co-authored papers 21
Center for Cancer Research, National Cancer Institute
Co-authored papers 18
Co-authored papers 16
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Co-authored papers 16
NYU Grossman School of Medicine
Co-authored papers 16
Children's Hospital of Philadelphia
Co-authored papers 15
Children's Hospital of Philadelphia
Co-authored papers 15
Co-authored papers 15
Co-authored papers 13
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Co-authored papers 13
Institut Curie
Co-authored papers 12
Co-authored papers 12